Copyright
©The Author(s) 2022.
Figure 1 Many features and characteristics of severe acute respiratory syndrome coronavirus-2 are associated with the development of autoantibodies and autoimmune phenomena.
In some patients, autoimmune disease is developed after coronavirus disease 2019 (COVID-19). On the other hand, COVID-19 vaccines proved their efficacy, effectiveness and safety in patients with autoimmune diseases. SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; COVID-19: Coronavirus disease 2019.
- Citation: Velikova T. Vaccines and autoimmunity during the COVID-19 pandemic. World J Immunol 2022; 12(2): 9-14
- URL: https://www.wjgnet.com/2219-2824/full/v12/i2/9.htm
- DOI: https://dx.doi.org/10.5411/wji.v12.i2.9